Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$55.1 million.

  • Immuneering's Free Cash Flow fell 21.54% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.1 million, marking a year-over-year decrease of 11.71%. This contributed to the annual value of -$55.1 million for FY2024, which is 11.71% down from last year.
  • As of FY2024, Immuneering's Free Cash Flow stood at -$55.1 million, which was down 11.71% from -$49.3 million recorded in FY2023.
  • Over the past 5 years, Immuneering's Free Cash Flow peaked at -$14.7 million during FY2020, and registered a low of -$55.1 million during FY2024.
  • In the last 3 years, Immuneering's Free Cash Flow had a median value of -$49.3 million in 2023 and averaged -$49.7 million.
  • Data for Immuneering's Free Cash Flow shows a maximum YoY plummeted of 110.65% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Immuneering's Free Cash Flow stood at -$14.7 million in 2020, then plummeted by 110.65% to -$30.9 million in 2021, then plummeted by 45.07% to -$44.8 million in 2022, then declined by 9.96% to -$49.3 million in 2023, then fell by 11.71% to -$55.1 million in 2024.